Trial Profile
A Randomized Phase II Trial of Sunitinib Four-weeks on/Two-weeks Off Versus Two-weeks on/One-week Off as First Line Therapy in Metastatic Renal Cell Carcinoma.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 31 Mar 2015 New trial record